HOME >> BIOLOGY >> NEWS
New Treatment Successful With Hepatitis C

SAN FRANCISCO, Calif. -- An inexpensive new treatment for hepatitis C, a disease that afflicts 1-2 percent of the population, is more effective than the standard therapy, according to a recent study.

The pilot study, recently completed at Penn State's Milton S. Hershey Medical Center, treated patients with amantadine, a drug that has been available in the United States since the 1960s. Thirty percent of the patients in the study responded to amantadine treatment.

Amantadine costs only $20 per month -- a tiny fraction of the cost of interferon, the conventional treatment for hepatitis C. Interferon costs approximately $500 per month, and must be administered for at least six months.

Jill P. Smith, M.D., associate professor of medicine at Hershey, discovered that amantadine is an effective alternative treatment for hepatitis C -- without the extensive side effects associated with interferon. Smith will present the results of her study on May 19 at San Francisco's Mosconi Convention Center as part of the annual meeting of the American Gastroenterological Association and the American Association for the Study of Liver Diseases.

Interferon's frequent side effects include a drop in white blood cell count and flu-like syndrome with aches, pains and fever. Hair loss, anemia, thyroid disease and severe depression occur less frequently.

Amantadine has fewer side effects, including: difficulty in concentration, constipation and rare cardiac symptoms in some elderly patients. Another drawback of interferon treatment is that only 50 percent of the patients respond to it, according to Smith. Half of those responders relapse after they stop the six months of therapy, dropping the effectiveness rate to approximately 25 percent.

The poor response, side effects and cost of interferon treatment prompted Smith to look for another drug.

Smith's study included 22 patients who were monitored over a four-year period.
'"/>

Contact: Gail Brown
gxg14@psu.edu
717-531-8604
Penn State
22-May-1998


Page: 1 2 3

Related biology news :

1. St. Petersburg/New Haven Partnership for HIV/AIDS Care, Treatment and Support launched
2. Treatment stimulates growth and regeneration of injured adult skeletal muscle
3. Treatment of lupus in mice may point the way to human treatment
4. Treatment in mice proves effective against Duchenne muscular dystrophy
5. Treatment protects mouse ovaries from radiation therapy
6. National Institute on Drug Abuse launches National Drug Addiction Treatment Clinical Trials Network
7. Treatment restores normal heart rhythm in patients
8. Researchers Develop New Treatment For Hepatitis B And C As Nation Anticipates Surge In Number Of Cases
9. Researchers: Exciting Discovery Might Improve Cancer Treatment
10. Coffee Without Addiction, Possible New Treatment For Osteoporosis, Wrinkle-Free Cotton, And More
11. Scientists Discover Molecular Trigger Of Mucus Production, Suggesting First Treatment For Deadly Bronchitis, Other Diseases

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Treatment Successful With Hepatitis

(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
(Date:10/17/2014)... release is available in German . ... of sperms every day in order to reproduce? And why ... the topic of the latest issue of the research journal ... The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has ... is not unusual for a female to copulate with several ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: